MET233 is developed by Pfizer Inc..

What is the generic name of MET233?

met233 is the generic (nonproprietary) name of MET233.

Last reviewed 2026-04-20 · How we verify

MET233 (met233)

Pfizer Inc. · Phase 1 active Quality 0/100

At a glance

Generic name	met233
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MET233 in Individuals With Obesity or Overweight (PHASE1, PHASE2)
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MET233 CI brief — competitive landscape report
MET233 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI